See more : RBL Bank Limited (RBLBANK.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Bio-Path Holdings, Inc. (BPTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio-Path Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- CMS Info Systems Limited (CMSINFO.NS) Income Statement Analysis – Financial Results
- Yindu Kitchen Equipment Co., Ltd (603277.SS) Income Statement Analysis – Financial Results
- Northern Star Investment Corp. III (NSTC) Income Statement Analysis – Financial Results
- Denison Mines Corp. (DNN) Income Statement Analysis – Financial Results
- Tomoegawa Co., Ltd. (3878.T) Income Statement Analysis – Financial Results
Bio-Path Holdings, Inc. (BPTH)
About Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.00K | 13.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.44K | 43.81K | 59.45K | 79.31K |
| Cost of Revenue | 178.00K | 178.00K | 161.00K | 151.00K | 230.00K | 426.00K | 0.00 | 0.00 | 201.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.11K | 37.77K | 43.88K | 55.42K |
| Gross Profit | -178.00K | -178.00K | -161.00K | -151.00K | -230.00K | -426.00K | 37.00K | 13.00K | -201.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.67K | 6.05K | 15.58K | 23.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9.05% | 13.80% | 26.20% | 30.13% |
| Research & Development | 11.61M | 9.17M | 5.91M | 6.58M | 4.59M | 4.60M | 5.48M | 5.47M | 3.02M | 1.83M | 1.63M | 1.60M | 1.14M | 1.14M | 480.26K | 333.47K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.11M | 4.74M | 4.53M | 4.33M | 4.11M | 3.38M | 3.52M | 3.01M | 2.46M | 2.72M | 1.63M | 986.10K | 0.00 | 704.88K | 1.31M | 587.16K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 123.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.24M | 4.74M | 4.53M | 4.33M | 4.11M | 3.38M | 3.52M | 3.01M | 2.46M | 2.72M | 1.63M | 986.10K | 1.22M | 704.88K | 1.31M | 587.16K | 107.44K | 141.31K | 82.53K | 78.16K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 608.00K | 0.00 | 0.00 | 196.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 182.98K | 171.95K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.84M | 13.90M | 10.44M | 10.91M | 8.69M | 7.98M | 9.00M | 8.49M | 5.48M | 4.54M | 3.27M | 2.58M | 2.37M | 1.85M | 1.97M | 1.09M | 107.44K | 141.31K | 82.53K | 78.16K |
| Cost & Expenses | 15.84M | 13.90M | 10.44M | 10.91M | 8.69M | 7.98M | 9.00M | 8.49M | 5.48M | 4.54M | 3.27M | 2.58M | 2.37M | 1.85M | 1.97M | 1.09M | 127.55K | 179.08K | 126.40K | 133.58K |
| Interest Income | 36.00K | 33.00K | 3.00K | 26.00K | 94.00K | 7.00K | 9.00K | 12.00K | 17.67K | 22.63K | 4.04K | 779.00 | 2.91K | 1.30K | 3.38K | 41.06K | 0.00 | 541.00 | 132.00 | 1.35K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.94K | 13.08K | 17.62K | 13.26K |
| Depreciation & Amortization | 82.00K | 178.00K | 161.00K | 151.00K | 230.00K | 426.00K | 411.00K | 204.00K | 201.76K | 170.91K | 160.63K | 185.27K | 211.71K | 197.27K | 182.98K | 171.95K | 1.68K | 2.72K | 3.03K | 3.06K |
| EBITDA | -15.76M | -13.69M | -10.28M | -10.73M | -8.37M | -8.16M | -8.56M | -8.27M | -5.27M | -4.35M | -3.11M | -2.40M | -2.15M | -1.88M | -1.79M | -2.68M | -107.44K | -132.00K | -63.79K | -49.85K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28,348.65% | -76,800.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -973.44% | -301.30% | -107.30% | -62.85% |
| Operating Income | -15.84M | -13.90M | -10.44M | -10.91M | -8.69M | -8.59M | -8.97M | -8.48M | -5.48M | -4.54M | -3.27M | -2.58M | -2.37M | -2.33M | -1.97M | -2.89M | -109.11K | -135.27K | -66.95K | -54.26K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -24,232.43% | -65,192.31% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -591.78% | -308.75% | -112.61% | -68.42% |
| Total Other Income/Expenses | -235.00K | 33.00K | 3.00K | 26.00K | 94.00K | 7.00K | 1.94M | 1.73M | 18.21K | 22.05K | 3.23K | -344.86K | 2.27K | -232.43K | 3.38K | 41.06K | 56.67K | -12.54K | -17.49K | -11.91K |
| Income Before Tax | -16.08M | -13.87M | -10.44M | -10.88M | -8.60M | -8.58M | -7.02M | -6.75M | -5.47M | -4.52M | -3.27M | -2.58M | -2.36M | -2.08M | -1.97M | -2.85M | -52.45K | -147.81K | -84.44K | -66.17K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18,981.08% | -51,923.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -284.44% | -337.37% | -142.02% | -83.43% |
| Income Tax Expense | 0.00 | -33.00K | -3.00K | -26.00K | -94.00K | -608.00K | -1.94M | -1.73M | 0.00 | -22.30K | -3.23K | -142.00 | -2.27K | 232.43K | 0.00 | 2.85M | 100.00 | 100.00 | 100.00 | 100.00 |
| Net Income | -16.08M | -13.84M | -10.44M | -10.86M | -8.51M | -8.58M | -7.02M | -6.75M | -5.47M | -4.52M | -3.27M | -2.58M | -2.36M | -2.08M | -1.97M | -2.85M | -52.55K | -147.91K | -84.54K | -66.27K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18,981.08% | -51,923.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -284.99% | -337.60% | -142.19% | -83.56% |
| EPS | -33.64 | -38.03 | -31.04 | -56.44 | -64.02 | -287.54 | -278.69 | -291.26 | -243.61 | -202.50 | -183.04 | -174.15 | -175.57 | -172.91 | -186.06 | -277.22 | -3.84 | -14.13 | -13.71 | -10.75 |
| EPS Diluted | -33.64 | -38.03 | -31.04 | -56.44 | -64.02 | -287.54 | -278.69 | -291.26 | -243.61 | -202.50 | -183.04 | -174.15 | -175.57 | -172.91 | -186.06 | -277.22 | -3.84 | -14.13 | -13.71 | -10.75 |
| Weighted Avg Shares Out | 478.00K | 363.80K | 336.25K | 192.35K | 132.85K | 29.85K | 25.20K | 23.18K | 22.44K | 22.32K | 17.84K | 14.83K | 13.46K | 12.04K | 10.59K | 10.29K | 13.69K | 10.47K | 6.17K | 6.17K |
| Weighted Avg Shares Out (Dil) | 478.00K | 363.80K | 336.25K | 192.35K | 132.85K | 29.85K | 25.20K | 23.18K | 22.44K | 22.32K | 17.84K | 14.83K | 13.46K | 12.04K | 10.59K | 10.29K | 13.69K | 10.47K | 6.17K | 6.17K |
Bio-Path Holdings shares sink 6% after deal for at-the-market offering
Shares of Bio-Path Holdings BPTH, -0.06% fell late Thursday after the company said it had reached a deal for an at-the-market share offering.
Bio-Path Holdings Provides 2024 Clinical and Operational Update
HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical development and operational...
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23
Dallas, Texas--(Newsfile Corp. - March 27, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q4 2023. To view the full announcement, including downloadable images, bios, and more, click here.
Bio-Path Holdings Inc. (BPTH) Q4 2023 Earnings Call Transcript
Bio-Path Holdings Inc. (NASDAQ:BPTH ) Q4 2023 Results Conference Call March 8, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price - SVP, Finance, Accounting and Administration Conference Call...
Bio-Path Holdings Reports Full Year 2023 Financial Results
HOUSTON, March 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the...
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
HOUSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a...
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 23, 2024 Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 23, 2024
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
BP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients by Utilizing RNAi to Limit Cells' Ability to Produce Bcl-2 Protein BP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients by Utilizing RNAi to Limit Cells' Ability to Produce Bcl-2 Protein
Bio-Path Holdings, Inc. (BPTH) Q3 2023 Earnings Call Transcript
Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q3 2023 Earnings Call Transcript November 15, 2023 8:30 AM ET Company Participants Will O'Connor - IR, Stern IR Peter Nielsen - President and CEO Anthony Price - SVP of Finance, Accounting and Administration Conference...
Source: https://incomestatements.info
Category: Stock Reports